12 Cardiovascular Disease Real-Risk Factors

Cardiovascular disease is one of leading causes of death in the US, killing about 610,000 people each year. Because of this large number, it is very important that you know the risk factors 12 REAL cardiovascular disease.

“If we could eliminate morning heart disease, the mean
The life expectancy of all Americans would increase by
estimated ten years.”

Dr. Barry Sears

vs heart disease cardiovascular disease

Heart disease a wide range of described conditions that affect your heart. Diseases under the umbrella of heart disease include blood diseases, such as coronary artery disease vessels; heart rhythm problems (arrhythmias); and heart defects (congenital heart defects) are born, among others. The term “heart disease” is often used interchangeably with the term “cardiovascular disease”. However, cardiovascular disease generally refers to conditions that involve narrowed or blood vessels that can lead to a heart attack, chest pain (angina) or stroke are blocked. Other heart diseases, such as those affecting the muscle, valves or rhythm of your heart, are also considered forms of heart disease.

What is cholesterol

Cholesterol is a waxy substance, similar to the fat found in all cells of the body, produced by the liver to help to make thousands of bodily functions. We need cholesterol to make important things such as hormones, vitamin D, and substances that help us digest certain foods by bile acid synthesis. Without it, we would not be able to maintain normal levels of testosterone, estrogen, progesterone and cortisol. Cholesterol also helps in the production of cell membranes, the cover of nerve sheaths, and much of the brain. Understanding the functions of this molecule much-maligned will help you understand why so many things can go wrong when we seek lower levels and lower cholesterol.

“So if you think that cholesterol is the enemy, think again. No
cholesterol, he would die. In fact, people with the lowest
cholesterol since age are at increased risk of death.

Under certain circumstances, higher cholesterol as possible
really help increase life expectancy. ”
Dr. Mark Hymann

cholesterol Risk

Fortunately, the medical focus on high cholesterol levels as the cause last of most heart attacks and strokes has begun to turn. It is important to understand that in a clinical setting, proven cardiovascular disease markers include high levels

  • Triglycerides
  • Insulin
  • cortisol
  • C-reactive protein
  • NO high cholesterol levels.

Medical studies now show that reduction of the levels of cholesterol is not going to lower your risk of a heart attack or stroke. “People with low cholesterol (below 200) suffer nearly 40 percent of all heart attacks. In addition, people with low cholesterol (less than 180) are three times more than the general population strokes.” William Castelli , MD (former director of the Framingham Heart Study)

oasis-serene-botanicals-skincare

statin Drugs

No you can talk about cholesterol or cardiovascular disease, without focusing on the current onslaught of statin drugs. Statins are HMG-CoA reductase inhibitors, ie, which act by blocking the enzyme in the liver that is responsible for making cholesterol (HMG-CoA).

Currently, we have tens of millions of Americans are taking these drugs to lower cholesterol and some experts say that many millions more should take them. Accompanied by massive marketing campaigns, statins are huge moneymakers for the pharmaceutical industry, for a sum of around $ 29 billion in sales in 2013 . That is the amount of money you make when one in four Americans over 45 are convinced by your doctor, you need a statin drug. Twenty years ago, doctors were not concerned about the effects that cholesterol could have on heart disease. Today, thanks to the efforts of pharmaceutical companies, high cholesterol levels are now recognized as a major health problem. In fact, IMS Health, a global health information, reports that the two top-selling drugs in 2004 were statins: Lipitor (Lipitor) Pfizer (New York, NY, USA) -valued to US $ 10.6 billion, an increase of 13.9% in the year and Zocor (simvastatin) Merck (Whitehouse Station, NJ, USA) above. A pharmaceutical executive said: “The appearance of cholesterol reduction as a market was an important event for the pharmaceutical industry promises of metabolic syndrome to be as big or bigger.”. (Breitstein, 2004).

Side effects of statin drugs are well tested; in fact, there are now 900 studies showing its adverse effects, some of which include muscle problems, memory problems and even increased risk of cancer.

Important: If you are taking a statin drug, you should also take a supplement of CoQ10 high quality. Statin drugs actually deplete the body of CoQ10, which can have adverse results. Doctors rarely inform their patients taking statin drugs on the importance of including a supplement of CoQ10. As the body becomes more and more depleted of CoQ10, the body can begin to suffer from fatigue, muscle weakness and pain, and heart failure over time.

The best and most effective way is to take ubiquinol CoQ10. And the most effective brand of CoQ10, in my opinion, is Kaneka.

12 Real factors risk of cardiovascular disease that can cause heart attacks and strokes

The following are some of the most important clinical indicators that show you have an increased risk of heart attack and stroke.

  1. Cardiac arrhythmia. This includes atrial fibrillation and other disturbances of normal heart rhythm.
  2. Elevated triglycerides, in particular a high ratio of triglyceride to HDL cholesterol. triglycerides studies have implicated in the progression of coronary atherosclerosis (hardening of the arteries).
  3. elevated homocysteine. One study found that men with extremely high homocysteine ​​levels were three times more likely to have a heart attack than others.
  4. elevated insulin.
  5. high levels of cortisol. High levels of cortisol are associated with hypertension, which increases your cardiovascular risk. Patients with heart disease show higher cortisol levels than others.
  6. with respect to elevated estrogen progesterone.
  7. Low testosterone (in men). It has been found Higher levels of testosterone in men older than offer protection five times against coronary artery disease.
  8. high testosterone (in women).
  9. lipid peroxides. lipid peroxides are chemicals damage caused by oxygen free radicals lipid components of cell membranes. High levels of lipid peroxides are associated with cancer, heart disease, stroke, and aging.
  10. elevated C-reactive protein. The C-reactive protein is a marker associated with the production of inflammatory cytokines, which pose a threat to cardiovascular health. Men with CRP levels in the highest quartile had three times the number of heart attacks and twice ischemic stroke as the general population.
  11. Activity fibrinogen and fibrinogen antigen assays. When higher blood levels of fibrinogen are present, the balance is tipped in favor of the formation of blood clots, even when it may not be appropriate. This can happen, for example, at the site of a broken coronary plaque. The injured surface of the plate causes fibrinogen is converted to fibrin, forming a blood clot, which can result in a heart attack. Fibrinogen can also promote the growth of atherosclerotic plaque, even without the formation of blood clots. increased fibrinogen levels are associated with increased risk of heart attack.
  12. Advanced testing lipoprotein. advanced lipoprotein testing can help provide a greater understanding of their risks of heart disease, filling the open gaps in the mainstream cholesterol or lipid test. The information provided by the higher lipoprotein tests can help you and your doctor to design an effective means to prevent future heart attacks program. If you have a family history of heart disease, high blood pressure, diabetes or any other measure of coronary plaque, you should seriously consider testing lipoproteins. If you have already had diagnosed coronary heart disease, that is, if you have had a heart attack, angina, or heart procedure such as coronary angioplasty or bypass surgery, then testing lipoproteins can be a crucial part of their prevention program of future cardiac disasters, especially if conventional lipid tests has failed to identify the cause of their illness.

Other risk factors include thyroid problems, magnesium deficiency and imbalance of fatty acids.

The Good News

The good news is that you can not take a long time to rectify the imbalances present in a complete cardiovascular evaluation. In fact, with lifestyle changes consistent life as a healthier herbal that include healthy fats diet, daily exercise, a good supplementation including optimization Vitamin D plants with good sleep habits preventing the use of snuff and drinking and stress reduction , many people are able to reduce their risk in just 6-8 weeks.

Resources and Resources

  1. Law MR, Wald NJ. thresholds risk factors: its existence under scrutiny. BMJ. 2002 June 29; 324 (7353) :. 1570-6
  2. Akosah KO, Schaper A, C Cogbill, P. Schoenfeld prevention of myocardial infarction in young adults, first, how the guidelines of the National Cholesterol Education Panel III made? J Am Coll Cardiol. 7 May 2003; 41 (9):. 1475-9
  3. Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from the lipoprotein cholesterol, triglycerides, lipoprotein (a), the HDL subfractions density apolipoprotein A-I and B, and: The Atherosclerosis Risk in Communities (ARIC). Circulation. 2001 Sep 4; 104 (10) :. 1108-113
  4. Stamler J, Wentworth D, Neaton JD. It is the relationship between serum cholesterol and the risk of premature death from coronary heart disease continuous and gradual? The main findings 356.222 screenees Intervention Study of Multiple Risk Factor (MRFIT). JAMA. 28 November 1986; 256 (20) :. 2823-8
  5. Castelli WP, Anderson K, Wilson PW, Levy D. Lipids and risk of coronary heart disease. The Framingham study. Ann Epidemiol. 1992 Jan; 2 (1-2) :. 23-8
  6. Sniderman AD, Pedersen T, Kjekshus J. Put low-density lipoprotein in the center stage in atherogenesis. Am J Cardiol. 1997 Jan 1; 79 (1) :. 64-7
  7. Cheung MC, Brown BG, Wolf AC, Albers JJ. altered distribution of particle size lipoprotein apolipoprotein A-I containing in subjects with coronary artery disease. J Lipid Res 1991 Mar.; 32 (3) :. 383-94
  8. Lamarche B, Despres JP, Moorjani S, et al. The prevalence of dyslipidemic phenotypes in ischemic heart disease (possible outcomes Quebec Cardiovascular Study). Am J Cardiol. 1995 Jun 15; 75 (17) :. 1189-1195
  9. Walldius G, Jungner I, I Holme, et al. High apolipoprotein B, low apolipoprotein A-I, and improved prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001 Dec 15; 358 (9298) :. 2026-33
  10. JE van Lennep, Westerveld HT, van Lennep HW, et al. Apoliprotein during treatment with recurrent events and coronary artery disease. Arterioscler Thromb Vasc Biol 2000 nov.; 20 (11) :. 2408-13
  11. Gotto AM, Jr., Whitney E, Stein EA, et al. Relationship between baseline and during treatment and lipid parameters first major acute coronary events in the Air Force / Texas Coronary Atherosclerosis Prevention Study (AFCAPS / TexCAPS). Circulation. 8 February 2000; 101 (5):. 477-84
  12. St-Pierre AC, Ruel IL, Cantin B, et al. Comparison of different electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease. Circulation. 6 November 2001; 104 (19) :. 2295-9
  13. Kwiterovich PO, Jr. clinical relevance of biochemical, metabolic and genetic factors that influence the heterogeneity of low-density lipoprotein. Am J Cardiol. 2002 October 17; 90 (8A): 47i 30i .-
  14. Lamarche B, Tchernof A, Moorjani S, et al. , Small dense particles of low-density lipoprotein as a predictor of risk of ischemic heart disease in men. Possible outcomes Quebec Cardiovascular Study. Circulation. 1997 Jan 7; 95 (1) :. 69-75
  15. TW de Bruin. lipid metabolism. Curr Opin Lipidol. 1998 Jun; 9 (3) :. 275-8
  16. Krauss RM. Effects of feeding and genetic heterogeneity in LDL. Rev Nutr Diet world. 2001; 89 :. 12-22
  17. St-Pierre AC, Bergeron J, Pirro M, et al. Effect of C-reactive protein levels in plasma in modulating the risk of coronary heart disease associated with small, dense, low density lipoproteins in men (the Quebec Cardiovascular Study). Am J Cardiol. 2003 Mar 1; 91 (5):. 555-8
  18. JM Morgan Carey CM, Lincoff A, Capuzzi DM. The effects of niacin in the distribution of lipoprotein subclasses. Previous Cardiol. . 2004; 7 (4): 182-7
  19. Guyton JR, Goldberg AC, Kreisberg RA, et al. Effectiveness of dosing once night of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol. 1998 Sep 15; 82 (6) :. 737-43
  20. Superko HR. Exercise and lipoprotein metabolism. J Cardiovasc Risk. 1995 Aug; 2 (4) :. 310-5
  21. Berneis KK, Krauss RM. metabolic and clinical significance origins of heterogeneity of LDL. J Lipid Res 2002 Sep.; 43 (9) :. 1363-1379
  22. BM Davy, Davy KP, Ho RC, et al. High-fiber oat cereal compared with wheat cereal consumption favorably alters the number of particles of LDL-cholesterol subclass and middle-aged men and elderly. Am J Clin Nutr. 2002 Aug; 76 (2) :. 351-8
  23. Griffin BA. The effect of n-3 fatty acids in subfractions low density lipoproteins. Lipids. 2001; 36. SupplS91-7
  24. Gordon DJ, Rifkind BM. High-density lipoprotein, the clinical implications of recent studies. N Engl J Med 1989 November 9.; 321 (19) :. 1311-6
  25. Miller NE. Associations subclasses of high density lipoproteins and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J. 1987 Feb; 113 (2 Pt 2) :. 589-97
  26. Syvänne M, Ahola M, Lahdenperä S, et al. subfractions high density lipoprotein in non-insulin dependent diabetes mellitus and coronary artery disease. J Lipid Res 1995 Mar.; 36 (3) :. 573-82
  27. Johansson J, Carlson LA, Landou C, Hamsten A. The high density lipoprotein and coronary atherosclerosis. A strong inverse relationship with the larger particles is limited to normotriglyceridemic patients. Arterioscler Thromb. 1991 Jan; 11 (1) :. 174-82
  28. H. Bays existing and combination therapy investigational drugs for cholesterol high density lipoprotein. Am J Cardiol. 20 November 2002; 90 (10B): 30K-43K
  29. TR Thomas, BK Smith, OM Donahue, et al.. Effects of omega-3 fatty acid supplements and exercise lipoprotein subfractions low density and high density lipoprotein. Metabolism. 2004 Jun; 53 (6) :. 749-54
  30. Tsunoda F, Koba S, Hirano T, et al. Association between the small dense low density lipoprotein accumulation and remaining particles like postprandial triglyceride rich in patients with myocardial infarction normotriglyceridemic. Circ J. 2004 Dec; 68 (12) :. 1165-1172
  31. Chung BH, BH Cho Liang P, et al. Contribution to postprandial mediated changes in dietary fat cholesterol concentrations of endogenous lipoproteins in humans lipemia. Am J Clin Nutr. 2004 Nov; 80 (5) :. 1145-1158
  32. AA Rivellese, Maffettone A, Vessby B, et al. Effects of dietary n-3 fatty acids saturated, monounsaturated and fasting lipoprotein, LDL size and postprandial lipid metabolism in healthy subjects. Atherosclerosis. 2003 Mar; 167 (1) :. 149-58
  33. Otvos J. Measurement of triglyceride-rich lipoproteins by nuclear magnetic resonance spectroscopy. Clin Cardiol. 1999 Jun; 22 (Suppl 6) :. II21-7
  34. Zilversmit DB. nature atherogenic triglycerides, postprandial lipemia, and remaining triglyceride-rich lipoproteins. Clin Chem 1995 Jan.; 41 (1) :. 153-8
  35. Chan DC, Barrett HP, GF Watts. Dyslipidemia in visceral obesity: mechanisms, consequences and therapy. Am J Cardiovascular Drugs. . 2004; 4 (4): 227-46
  36. Berglund L, R. Ramakrishnan Lipoprotein (a): a factor of cardiovascular risk difficult to achieve. Arterioscler Thromb Vasc Biol 2004 Dec.; 24 (12) :. 2219-26
  37. Maher VM, Brown BG, Marcovina SM, et al. Effects of elevated LDL cholesterol reduction in cardiovascular risk of lipoprotein (a). JAMA. 13 December 1995; 274 (22) :. 1771-4
  38. Sirtori CR, Calabresi L, S Ferrara, et al. L-carnitine reduced plasma lipoprotein (a) levels in patients with hyper Lp (a). Nutr Metab Dis Cardiovascular. 2000 Oct; 10 (5) :. 247-51
  39. Jenkins DJ, Kendall CW, Marchie A, et al. Dose response of almonds on coronary risk factors for heart disease: blood lipids, oxidized low density lipoproteins, lipoprotein (a), homocysteine, and pulmonary nitric oxide: A controlled, randomized crossover. Circulation. 2002 Sep 10; 106 (11) :. 1327-1332
  40. Marcovina SM, ML Koschinsky, Albers JJ, Skarlatos S. Report of the National Heart, Lung and Blood Institute Workshop lipoprotein (a) and cardiovascular disease: recent advances and future directions. Clin Chem 2003 in November.; 49 (11) :. 1785-1796
  41. Berglund L. Diet and pharmacological treatment of lipoprotein (a). Curr Opin Lipidol. 1995 Feb; 6 (1):. 48-56
  42. Anon. Homocysteine ​​and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002 October 23; 288 (16) :. 2015-22
  43. Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine ​​and cardiovascular disease. Annu Rev Med. 1998; 49 :. 31-62
  44. Ciubotaru I, Lee YS, Wander RC. fish oil in the diet decreases C-reactive protein, interleukin-6, and triacylglycerol to HDL cholesterol ratio in postmenopausal women on HRT. J Nutr Biochem. 2003 Sep; 14 (9) :. 513-21
  45. Fredrikson GN, Hedblad B, Nilsson JA, et al. Association between diet, lifestyle, metabolic cardiovascular risk factors, and levels of C-reactive protein plasma. Metabolism. 2004 Nov; 53 (11) :. 1436-1442
  46. Patrick L, cardiovascular disease M. Uzick: C-reactive protein and inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and polyphenols olive oil. A review of the literature. Altern Med Rev June 2001; 6 (3):. 248-71
  47. Phillips T, Childs AC, Dreon DM, Phinney S, Leeuwenburgh C. A dietary supplement attenuates IL-6 and CRP after eccentric exercise in untrained men. Med Sci Sports Exerc. 2003 Dec; 35 (12) :. 2032-7
  48. Chambless LE, Folsom AR Sharrett, et al. predicting the risk of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC). J Clin Epidemiol. 2003 Sep; 56 (9) :. 880-90
  49. W. Koenig fibrin (fibrinogen) in cardiovascular disease: an update. Thromb Haemost. 2003 Apr; 89 (4) :. 601-9
  50. Palmieri V, Celentano A, Roman MJ, et al. Ratio of fibrinogen to cardiovascular events is independent of preclinical cardiovascular disease: Strong Heart Study. Am Heart J. 2003 Mar; 145 (3) :. 467-74
  51. Vanschoonbeek K, Feijge MA, Paquay M, et al. hypocoagulant variable effect of the intake of fish oil in humans: modulation level of fibrinogen and thrombin generation. Arterioscler Thromb Vasc Biol 2004 Sep.; 24 (9) :. 1734-1740
  52. Maat MP. Effects of diet, drugs and genes on plasma fibrinogen levels. Ann NY Acad Sci. 2001; 936 :. 509-21
  53. Berg A, Konig D, Deibert P, et al. Effect of oat bran enriched diet on the atherogenic lipid profile in patients with an increased risk of coronary heart disease. An intervention study randomized controlled lifestyle. Ann Nutr Metab. . 2003; 47 (6): 306-11
  54. Kerckhoffs DA, Brouns F, G Hornstra, Mensik RP. Effects on lipoprotein profile beta-glucan, soy protein and isoflavones human serum, the plant sterols and stanols, garlic and tocotrienols. J Nutr. 2002 Sep; 132 (9) :. 2494-505
  55. Brown L, Rosner B, Willett WW, Sacks FM. effects of dietary fiber to lower cholesterol: a meta-analysis. Am J Clin Nutr. 1999 Jan; 69 (1) :. 30-42
  56. Anderson JW, LD Allgood, Lawrence A, et al. meta-analysis of randomized controlled 8: effects of intake adjunct to diet therapy in men and women with hypercholesterolemia cholesterol-lowering psyllium. Am J Clin Nutr. 2000 Feb; 71 (2):. 472-9
  57. Bokura H, S. Kobayashi Chitosan lowers total cholesterol in women: a double-blind, randomized, placebo-controlled. Eur J Clin Nutr. 2003 May; 57 (5) :. 721-5
  58. Gallaher DD, Gallaher CM, Mahrt GJ, et al. A supplement glucomannan and chitosan fiber lowers plasma cholesterol and increases cholesterol excretion in humans normocholesterolemic overweight. J Am Coll Nutr. 2002 Oct; 21 (5) :. 428-33
  59. JW Anderson, Tietyen-Clark J. Dietary fiber: hyperlipidemia, hypertension and coronary heart disease. Am J Gastroenterol. 1986 Oct; 81 (10) :. 907-19
  60. harbis A, Perdreau S, S Vincent-Baudry, et al. meal glycemic responses and insulinemic modulate accumulation postprandial hepatic and intestinal lipoprotein in obese, insulin resistant subjects. Am J Clin Nutr. 2004 Oct; 80 (4) :. 896-902
  61. Pelkman CL. Effects of glycemic index of foods in serum cholesterol high density lipoprotein and triglycerides. . Curr Atheroscler Rep 2001 Nov; 3 (6):. 456-61
  62. Bowden, Johnny, Sinatra MD, Stephen, Rawlings, Deirdre. The great myth of cholesterol. 2015. ISBN :. 978-1-59233-712-5
  63. Life Extension Foundation. www.lef.org

Add a Comment

==[Click 2x to Close X]==
Most Popular Today!

Sorry. No data so far.